Fundamental Analysis of Better Therapeutics Inc - Growth / Value Index
BTTX - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Book value is negative
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | -3.10 | % | ||
Price to Book | -32.78 | 0 | 0 % | -35.25 |
Price to Sales | 0 | 0 | 0 % | |
Enterprise Value to EBITDA Multiple | -0.0107 | 0 | 0 % |
BTTX - Profitability Highlights
Profitability Analysis
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
Steady Growth in EPS for last four quarters
Tsr Profitability Index - Poor Score of 21.88
Piotroski F Score - Very Poor Value of 2.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 0 | 0 % | 0 | |
Return On Asset | -296.43 | 0 | 0 % | -54.67 |
Net Profit Margin | 0 | 0 | 0 % | 0 |
Operating Profit Margin | 0 | 0 | 0 % | 0 |
EBITDA Margin | 0 | 0 | 0 % | 0 |
Highlights
Market Cap | 496091 |
Enterprise Value | 496091 |
Price/Book TTM | -32.78 |
Outstanding Share | 54515.60 K |
Float/ Outstanding Share | 44.91% |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | 0 |
Peter Lynch Ratio | 0 |
Piotroski F Score | 2.00 |
Altman Z Score | |
Sloan Ratio | |
Peter Lynch Fair Value | 0 |
BTTX - Growth Highlights
Growth Analysis
Quarterly sales in last 5 years is trending up
Tsr Growth Index - Very Poor Score of 17.30
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | NA | % | % |
Gross Profit | -3114.00 K | 100.00 % | 5.52 % |
EBITDA | -46522.00 K | 25.40 % | 23.97 % |
Net Profit | -51163.00 K | 20.59 % | 22.76 % |
EPS | -0.0029 | 100.00 % | NA |
BTTX - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 75.00
Company is unable to generate enough free cash to support the business.
Interest Coverage of -15.18
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0 | 0 % | -1.44 |
Cash Ratio | 0 | 0 % | |
Quick Ratio | 0 | 0 % | 0.568 |
Shareholders Equity | 0 | 0 % | |
Debt to EBITDA | 0 | 0 % |
Historical Valuation Ratios of Better Therapeutics Inc
Historical Valuation Ratios
Loading ...
![loading](https://www.stockaio.com/static/img/LoadingMedium.gif)
Historical Profitability Ratios of Better Therapeutics Inc
Historical Profitability Ratios
Loading ...
![loading](https://www.stockaio.com/static/img/LoadingMedium.gif)
Historical Efficiency Ratios of Better Therapeutics Inc
Historical Efficiency Ratios
Loading ...
![loading](https://www.stockaio.com/static/img/LoadingMedium.gif)
Historical Solvency Ratios of Better Therapeutics Inc
Historical Solvency Ratios
Loading ...
![loading](https://www.stockaio.com/static/img/LoadingMedium.gif)
Note : All Data Generated at the End of Trading Hours (EOD Data)